Salarius Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Mar 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 22, 2024
DCOY$1.10-2.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statement of Stockholders' Equity
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)
| Common Stock · Additional Paid-In Capital · Accumulated Deficit · Total Stockholders' Equity (Deficit) | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares · Amount | ||||||||
| Balance at December 31, 2021 | 1,809,593 | $181 | $70,919,996 | $(32,197,192) | $38,722,985 | |||
| Common Stock issued for in-process research and development technology | 40,000 | 4 | 487,896 | — | 487,900 | |||
| Issuance of equity securities, net | 373,577 | 37 | 1,984,839 | — | 1,984,876 | |||
| Equity-based compensation expense | 27,927 | 3 | 768,252 | — | 768,255 | |||
| Issuance of equity securities for services | 4,802 | — | 28,548 | — | 28,548 | |||
| Net loss | — | — | — | (31,607,956) | (31,607,956) | |||
| Balance at December 31, 2022 | 2,255,899 | $225 | $74,189,531 | $(63,805,148) | $10,384,608 | |||
| Issuance of equity securities, net | 1,612,635 | 161 | 6,920,368 | 6,920,529 | ||||
| Equity-based compensation expense | 69,899 | 7 | 524,831 | 524,838 | ||||
| Net loss | (12,542,693) | (12,542,693) | ||||||
| Balance at December 31, 2023 | 3,938,433 | $393 | $81,634,730 | $(76,347,841) | $5,287,282 | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.